30 June 2022
2021 Annual review
We have made solid progress in our first four years. We have proof that our financial tools can be effective at increasing access today and building markets for the future.
In 2021, our guarantees accelerated access to products to tackle HIV, TB, malaria, syphilis and COVID-19. We also launched our 2021-2025 strategy, which will see us expand our work further.
Read our 2021 Annual review and Financial statements to find out how we used innovative finance to increase access to healthcare products.
1 February 2023
Impact case studies
30 June 2022
2021 Annual review
30 June 2021
2020 Annual report
30 September 2020
